Salveo Swiss Technologies specialises in regenerative medicine and the cryogenic preservation of umbilical cord stem cells. As a leader in its field and representation in numerous countries across Europe, Gregory says the protocols emanating from its extensive research and development facility in Geneva have resulted in a substantially more cost effective repository operation.
"From the regeneration of heart muscle to the treatment of MS and the carrier for a malaria vaccine, the usage of stem cells appears limitless. However, the cost of stem cell harvesting and cryogenic preservation is high and as a result is accessible to a small sector of pregnant parents. This product is therefore able to be provided to the market at a substantially reduced price when compared to its competitors, providing access to a greater portion of the population."
However, he emphasises that the Swiss operation is much more than merely providing an efficient processing and storage offering. "The quality of the protocols and infrastructure is what one expects of a Swiss-based product offering. The storage is effected with the ultimate goal of therapy in mind and the R&D in the regenerative medicine field has provided many opportunities to ensure efficacy. Evidencing this the processing unit has been awarded FACT accreditation, the highest level of accreditation for a laboratory of its kind internationally."
He believes the company's investment not only commands a bigger share of the stem cell market but also opens the services to additional consumers who may previously not have been able to afford the services.
"The development of FDA approved regenerative and post-operative treatments will open very substantial, high IP, market opportunities in the near future. Ecsponent is ideally positioned to take advantage of these developments," he concludes.
